Get the Stockscreener App
6.35
9.48%
0.55
After Hours:
6.30
-0.05
-0.79%
Annexon Inc stock is traded at $6.35, with a volume of 4.34M.
It is up +9.48% in the last 24 hours and up +12.19% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$5.80
Open:
$5.93
24h Volume:
4.34M
Relative Volume:
1.66
Market Cap:
$1.02B
Revenue:
-
Net Income/Loss:
$-206.69M
P/E Ratio:
-4.6846
EPS:
-1.3555
Net Cash Flow:
$-186.49M
1W Performance:
+4.96%
1M Performance:
+12.19%
6M Performance:
+108.88%
1Y Performance:
+312.34%
1-Day Range:
$5.91
$6.435
1-Week Range:
$5.72
$6.435
52-Week Range:
$1.40
$7.18
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650) 822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
6.35 | 930.75M | 0 | -206.69M | -186.49M | -1.3555 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Carson buys $49k in Annexon (ANNX) stock - Investing.com
Insider Buying: Annexon (NASDAQ:ANNX) Director Purchases 8,000 Shares of Stock - MarketBeat
Annexon (NASDAQ: ANNX) director adds 8,000 shares in planned stock purchase - Stock Titan
EV Market: Will Annexon Inc benefit from government policyWall Street Watch & Technical Buy Zone Confirmation - baoquankhu1.vn
Annexon stock rises after director purchases shares - MSN
Macro Review: Will Annexon Inc benefit from government policyPortfolio Gains Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference - Bitget
Geopolitics Watch: What are the risks of holding Annexon Inc2026 Analyst Calls & Long-Term Investment Growth Plans - baoquankhu1.vn
Annexon (NASDAQ:ANNX) Shares Up 6.6%What's Next? - MarketBeat
Wall Street analysts see a 165.52% upside in Annexon (ANNX): Can the stock really move this high? - MSN
HC Wainwright Estimates Annexon FY2030 Earnings - MarketBeat
Annexon posts full-year 2025 financial results and portfolio updates - Traders Union
H.C. Wainwright Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Cyber Risks Threaten Annexon Biosciences’ Clinical Operations, Reputation and Financial Health - The Globe and Mail
Dip Buying: Can Annexon Inc reach all time highs this yearTrade Exit Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - Sahm
Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High? - Yahoo Finance
Multiple Insiders Sold Annexon Shares Presenting Weak Signs For Investors - 富途牛牛
Wells Fargo Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Big Picture: What are the risks of holding Annexon IncEarnings Growth Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Jefferies reiterates Annexon Biosciences stock rating on M&A activity By Investing.com - Investing.com Canada
Annexon (ANNX) Gains Attention Amid Pharma Deal Activity - GuruFocus
Annexon (NASDAQ:ANNX) Shares Gap UpShould You Buy? - MarketBeat
Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Annexon Reports Positive Q4 and Full-Year 2025 Results, Highlights Key Milestones - National Today
TD Cowen Maintains Annexon(ANNX.US) With Buy Rating - Moomoo
Annexon Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Annexon (ANNX) Advances in Neuroinflammation Treatments - GuruFocus
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - Investing News Network
Annexon (NASDAQ:ANNX) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Annexon (NASDAQ: ANNX) advances C1q-targeted drugs for GBS and GA - Stock Titan
Annexon (NASDAQ: ANNX) widens 2025 loss but extends cash runway into 2027 - Stock Titan
Annexon Reports Fourth Quarter and Year-End 2025 Financial - GlobeNewswire
U.S. Earnings Preview: Before Market Open March 30 - Moomoo
ANNX Should I Buy - Intellectia AI
Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Vanguard disaggregates holdings; Annexon (ANNX) shows 0 shares reported - Stock Titan
Annexon (NASDAQ:ANNX) Trading Up 10.2%What's Next? - MarketBeat
Insider Sell: Will Annexon Inc be affected by tariffs2026 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Are Healthcare Stocks Falling Behind American Well (AMWL) in Performance This Year? - Bitget
Are Medical Stocks Lagging American Well (AMWL) This Year? - Yahoo Finance
U.S. Earnings Preview: Before Market Open March 23 - Moomoo
If You Invested $1,000 in Annexon, Inc. (ANNX) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX) and Electrocore (ECOR) - The Globe and Mail
ANNX PE Ratio & Valuation, Is ANNX Overvalued - Intellectia AI
Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic Atrophy With C1q Inhibition and Key Insights From ARCHER TrialsSlideshow (NASDAQ:ANNX) 2026-03-20 - Seeking Alpha
Chardan Capital Maintains Buy Rating on Annexon (ANNX) with $16 - GuruFocus
Annexon's (ANNX) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Annexon Inc Stock (ANNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carson William H. | Director |
Mar 10 '26 |
Buy |
5.67 |
8,000 |
45,360 |
62,405 |
| Dananberg Jamie | CHIEF MEDICAL OFFICER |
Mar 02 '26 |
Sale |
5.43 |
5,820 |
31,603 |
123,582 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Mar 02 '26 |
Sale |
5.42 |
4,339 |
23,517 |
182,625 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Mar 02 '26 |
Sale |
5.42 |
5,566 |
30,168 |
154,161 |
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Sale |
5.43 |
5,894 |
32,004 |
180,093 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
5.42 |
5,565 |
30,162 |
170,700 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):